Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T63068
|
||||
Former ID |
TTDS00336
|
||||
Target Name |
Serum albumin
|
||||
Gene Name |
ALB
|
||||
Synonyms |
ALB
|
||||
Target Type |
Successful
|
||||
Disease | Arthritis; Bursitis [ICD10: M00-M25] | ||||
Cholecystography; Gallbladder disease [ICD9:574, 575; ICD10: K81, K82, K80-K82] | |||||
Constipation [ICD9: 564; ICD10: K59.0] | |||||
Diarrhea [ICD9: 787.91; ICD10: A09, K59.1] | |||||
Hemophilia [ICD9: 286; ICD10: D66-D68] | |||||
Hypovolemic shock; hypoalbuminemia [ICD10: E88.09] | |||||
Imaging [ICD10: W88] | |||||
Reperfusion injury and stroke [ICD9: 410, 434.91; ICD10: I21, I22, I61-I63] | |||||
Visualizing lesions with abnormal blood brain barrier [ICD9: 437.9; ICD10: I67.9] | |||||
Xerophthalmia [ICD10: E50.6-E50.7] | |||||
Function |
Serum albumin, the main protein of plasma,has a good binding capacity for water, ca(2+), na(+), k(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood.
|
||||
BioChemical Class |
Serum albumin family
|
||||
Target Validation |
T63068
|
||||
UniProt ID | |||||
Sequence |
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV AASQAALGL |
||||
Drugs and Mode of Action | |||||
Drug(s) | Albumin Human | Drug Info | Approved | Hypovolemic shock; hypoalbuminemia | [551871] |
Bismuth | Drug Info | Approved | Diarrhea | [529749] | |
Ebselen | Drug Info | Approved | Reperfusion injury and stroke | [536373] | |
EVANS BLUE | Drug Info | Approved | Blood volume and Cardiac output measurement | [1572605] | |
Gadobenate Dimeglumine | Drug Info | Approved | Visualizing lesions with abnormal blood brain barrier | [527466], [538563], [551871] | |
Gadofosveset | Drug Info | Approved | Imaging | [529941] | |
Iodipamide | Drug Info | Approved | Cholecystography; Gallbladder disease | [538417], [542423], [551871] | |
Oxyphenbutazone | Drug Info | Approved | Arthritis; Bursitis | [551871] | |
Sodium lauryl sulfate | Drug Info | Approved | Constipation | [550704] | |
Activated recombinant FVII-albumin fusion protein | Drug Info | Phase 2/3 | Hemophilia | [525247] | |
RU-101 | Drug Info | Phase 1/2 | Xerophthalmia | [524273] | |
Modulator | Activated recombinant FVII-albumin fusion protein | Drug Info | [523809] | ||
Albumin Human | Drug Info | [556264] | |||
EVANS BLUE | Drug Info | [1572605] | |||
Gadofosveset | Drug Info | [529941] | |||
Oxyphenbutazone | Drug Info | ||||
RU-101 | Drug Info | [544031] | |||
Binder | Bismuth | Drug Info | [535086] | ||
Ebselen | Drug Info | [537897] | |||
Gadobenate Dimeglumine | Drug Info | [536789] | |||
Iodipamide | Drug Info | [536697] | |||
Sodium lauryl sulfate | Drug Info | [536123] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
Reactome | Platelet degranulation | ||||
Recycling of bile acids and salts | |||||
HDL-mediated lipid transport | |||||
Scavenging of heme from plasma | |||||
WikiPathways | Human Complement System | ||||
Binding and Uptake of Ligands by Scavenger Receptors | |||||
Lipid digestion, mobilization, and transport | |||||
Transport of vitamins, nucleosides, and related molecules | |||||
Bile acid and bile salt metabolism | |||||
Folate Metabolism | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
References | |||||
Ref 524273 | ClinicalTrials.gov (NCT01843894) A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye. U.S. National Institutes of Health. | ||||
Ref 525247 | ClinicalTrials.gov (NCT02484638) Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors. | ||||
Ref 529749 | The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. Gastroenterology. 1991 Oct;101(4):889-94. | ||||
Ref 536373 | Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007 Mar;12(1):97-112. | ||||
Ref 538417 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009321. | ||||
Ref 538563 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021357. | ||||
Ref 542423 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7400). | ||||
Ref 523809 | ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health. | ||||
Ref 535086 | Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35. Epub 2000 Dec 7. | ||||
Ref 536123 | Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7. | ||||
Ref 536697 | Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. Epub 2008 Mar 21. | ||||
Ref 536789 | Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7. | ||||
Ref 537897 | Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.